![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, February 27, 2023 11:13:11 PM
In the UK, a Manufacturing and Importation Authorisation (MIA) is required for companies that manufacture, import, or distribute medicinal products. The MIA is issued by the MHRA and is a prerequisite for the submission of an MAA.
The MIA demonstrates that the manufacturer has appropriate quality control systems and procedures in place to ensure that their products are manufactured to the required standards. It also includes information on the facilities, personnel, and equipment used in the manufacturing process.
So, in short, a valid MIA is a prerequisite for submitting an MAA in the UK, as it confirms that the manufacturer has the necessary certification to produce medicinal products according to the required standards.
Is MAA submission a prerequisite for the MIA approval?
No, in the UK, submitting a Marketing Authorisation Application (MAA) is not a prerequisite for obtaining a Manufacturing and Importation Authorisation (MIA).
An MIA is required for companies that manufacture, import, or distribute medicinal products. The MIA confirms that the manufacturer has appropriate quality control systems and procedures in place to ensure that their products are manufactured to the required standards. It also includes information on the facilities, personnel, and equipment used in the manufacturing process.
On the other hand, an MAA is required to gain marketing authorization for a new medicinal product in the UK. The MAA demonstrates that the product meets the necessary safety, efficacy, and quality standards for use in humans.
So, the MIA is a prerequisite for manufacturing and distributing medicinal products in the UK, while the MAA is a prerequisite for marketing a new medicinal product in the UK.
MIA approval requires MAA is in the process, what does that mean in the process, does that mean the submission?
You are correct that in the UK, a Marketing Authorisation Application (MAA) needs to be in progress or submitted for an applicant to be granted a Manufacturing and Importation Authorization (MIA).
"In the process" generally means that the applicant has started the MAA submission process with the Medicines and Healthcare products Regulatory Agency (MHRA), which is the UK's regulatory agency responsible for assessing and authorizing medicines. Typically, the MHRA will review the MAA and inspect the manufacturing facility before granting the MIA.
Therefore, to obtain an MIA, the applicant needs to demonstrate that they have an ongoing MAA submission process with the MHRA, which can involve submitting the application, providing additional information, and responding to any questions or requests from the agency. Once the MAA is deemed acceptable by the MHRA, the agency can then proceed with the inspection of the manufacturing facility and the granting of the MIA.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM